ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronEye IconIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintTitle ChevronIcon Twitter
Health Technology

Mitsubishi Tanabe Pharma Corp.

Business Summary

Mitsubishi Tanabe Pharma Corp. engages in the research, development, manufacture, and sale of pharmaceutical products. Its products include Remicade, Ceredist, Talion, Kremezin, Maintate, Simponi, Lexapro, Tenelia, Tetrabik, and Imusera. The company was founded by Gohei Tanabeya in 1678 and is headquartered in Osaka, Japan.

Financial Highlights

Mar 2019 JPYUSD
Revenue424,767M3,830.36M
Gross Profit241,187M2,174.91M
Operating income55,929M504.34M
Income before tax50,439M454.83M
Net income37,372M337.00M
EBITDA67,458M608.30M
Diluted EPS66.640.60
Dividends Per Share560.50
Total Assets1,056.28B9,543.17M
Total liabilities145,954M1,318.64M
Total equity897,604M8,109.53M
Operating cash flow41,460M373.86M
Currency in JPYCurrency in USD

Historical Data

 Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019
Revenue 415,124M 425,764M 423,977M 433,855M 424,767M
Gross Profit 232,950M 268,489M 258,052M 261,654M 241,187M
Operating income 67,133M 107,532M 94,967M 78,516M 55,929M
Income before tax 62,677M 83,255M 96,059M 78,764M 50,439M
Net income 39,502M 59,306M 71,263M 57,963M 37,372M
EBITDA 87,078M 117,868M 105,421M 90,051M 67,458M
Diluted EPS 70.41 105.72 127.03 103.34 66.64
Dividends Per Share 42 46 52 66 56
Total Assets 929,301M 958,445M 984,537M 1,048.44B 1,056.28B
Total liabilities 128,867M 132,129M 113,107M 153,617M 145,954M
Total equity 788,979M 815,518M 860,505M 882,808M 897,604M
Operating cash flow 68,167M 80,842M 59,785M 66,943M 41,460M
 Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019
Revenue 3,778.78M 3,545.54M 3,915.29M 3,914.51M 3,830.36M
Gross Profit 2,120.49M 2,235.83M 2,383.02M 2,360.80M 2,174.91M
Operating income 611.09M 895.47M 876.98M 708.42M 504.34M
Income before tax 570.53M 693.30M 887.07M 710.65M 454.83M
Net income 359.57M 493.86M 658.09M 522.97M 337.00M
EBITDA 792.65M 981.54M 973.52M 812.49M 608.30M
Diluted EPS 0.64 0.88 1.17 0.93 0.60
Dividends Per Share 0.38 0.38 0.48 0.59 0.50
Total Assets 7,749.01M 8,527.46M 8,835.47M 9,858.42M 9,543.17M
Total liabilities 1,074.56M 1,175.57M 1,015.04M 1,444.44M 1,318.64M
Total equity 6,578.93M 7,255.82M 7,722.38M 8,300.96M 8,109.53M
Operating cash flow 620.50M 673.21M 552.09M 604.00M 373.86M

Valuation Measures

Mar 2019
PER22.19
ROA3.55%
ROE4.19%
Operating margin13.16%
Profit margin8.79%

Key executives

  • President & Representative Director: Masayuki Mitsuka
  • Manager-Accounting & Finance: Toshihide Doi
  • Chief Compliance Officer & Executive Officer: Megumi Otaki
  • Executive Officer & General Manager-Sales: Yasutoshi Kawakami
  • Director & Managing Executive Officer: Yoshihiro Kobayashi

Shareholders

    Contact Details

    Related Companies

    • Mitsubishi Tanabe Pharma Board Incentive Plan
    • Mitsubishi Tanabe Pharma Holdings America, Inc.
    • Mitsubishi Tanabe Pharma Development (Beijing) Co. Ltd.
    • PT Tanabe Indonesia
    • Guangdong Tanabe Pharmaceutical Co. Ltd.
    • Mitsubishi Tanabe Pharma Development America, Inc.
    • Synthelabo-Tanabe Chimie SA
    • MTPC Holdings Canada, Inc.
    • Mitsubishi Pharma Research & Development (Beijing) Co. Ltd.
    • Stelic Institute & Co., Inc.
    • Benesis Corp.
    • Mitsubishi Tanabe Pharma Pension Fund
    • Tanabe Seiyaku Singapore Pte Ltd.
    • Tai Tien Pharmaceuticals Co. Ltd.
    • Mitsubishi Tanabe Pharma Employee Stock Ownership Plan
    • Mitsubishi Tanabe Pharma Korea Co., Ltd.
    • Yoshitomiyakuhin Corp.
    • Tama Kagaku Kogyo Co. Ltd.
    • Bipha Corp.
    • Mitsubishi Tanabe Pharma Factory Ltd.
    • Mitsubishi Pharma America, Inc.
    • Tanabe USA, Inc.
    • NeuroDerm Ltd.
    • Tanabe Research Laboratories USA, Inc.
    • Tanabe Holding America, Inc.
    • Tanabe Seiyaku Pension Fund
    • Medicago Inc.

    Competitors

      Last Updated on 27 Feb, 2020

      You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this monthThis is your last free article this month

      Stay ahead with our exclusives on Asia;
      the most dynamic market in the world.

      Stay ahead with our exclusives on Asia

      Get trusted insights from experts within Asia itself.

      Get trusted insights from experts
      within Asia itself.

      Try 1 month for $0.99

      You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this month

      This is your last free article this month

      Stay ahead with our exclusives on Asia; the most
      dynamic market in the world
      .

      Get trusted insights from experts
      within Asia itself.

      Try 3 months for $9

      Offer ends October 31st

      Your trial period has expired

      You need a subscription to...

      • Read all stories with unlimited access
      • Use our mobile and tablet apps
      See all offers and subscribe

      Your full access to Nikkei Asia has expired

      You need a subscription to:

      • Read all stories with unlimited access
      • Use our mobile and tablet apps
      See all offers
      NAR on print phone, device, and tablet media

      Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

      Celebrate our next chapter
      Free access for everyone - Sep. 30

      Find out more